Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A baseline metabolomic signature is associated with immunological CD4 + T-cell recovery after 36 months of antiretroviral therapy in HIV-infected patients

  • Rodríguez-Gallego, Esther|||0000-0002-6363-2510
  • Pacheco, Yolanda M.|||0000-0002-9451-8083
  • Peraire, Joaquim|||0000-0001-7808-5479
  • Viladés, Consuelo|||0000-0002-2991-9593
  • Beltrán-Debón, Raúl|||0000-0001-9691-1906
  • Mallol, Roger
  • López Dupla, Miguel
  • Veloso Esteban, Sergio|||0000-0001-7943-1169
  • Alba, Verónica|||0000-0002-5925-9573
  • Blanco, Julià|||0000-0002-2225-0217
  • Cañellas, Nicolau
  • Rull, Anna|||0000-0002-8907-7754
  • Leal, Manuel
  • Correig, Xavier|||0000-0002-6902-3054
  • Domingo Pedrol, Pedro|||0000-0003-1138-5770
  • Vidal, Francesc|||0000-0002-6692-6186
Poor immunological recovery in treated HIV-infected patients is associated with greater morbidity and mortality. To date, predictive biomarkers of this incomplete immune reconstitution have not been established. We aimed to identify a baseline metabolomic signature associated with a poor immunological recovery after antiretroviral therapy (ART) to envisage the underlying mechanistic pathways that influence the treatment response. This was a multicentre, prospective cohort study in ART-naive and a pre-ART low nadir (<200 cells/μl) HIV-infected patients (n = 64). We obtained clinical data and metabolomic profiles for each individual, in which low molecular weight metabolites, lipids and lipoproteins (including particle concentrations and sizes) were measured by NMR spectroscopy. Immunological recovery was defined as reaching CD4 + T-cell count at least 250 cells/μl after 36 months of virologically successful ART. We used univariate comparisons, Random Forest test and receiver-operating characteristic curves to identify and evaluate the predictive factors of immunological recovery after treatment. HIV-infected patients with a baseline metabolic pattern characterized by high levels of large high density lipoprotein (HDL) particles, HDL cholesterol and larger sizes of low density lipoprotein particles had a better immunological recovery after treatment. Conversely, patients with high ratios of non-HDL lipoprotein particles did not experience this full recovery. Medium very-low-density lipoprotein particles and glucose increased the classification power of the multivariate model despite not showing any significant differences between the two groups. In HIV-infected patients, a baseline healthier metabolomic profile is related to a better response to ART where the lipoprotein profile, mainly large HDL particles, may play a key role.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

IL-7/IL-7R gene variants impact circulating IL-7/IL-7R homeostasis and ART-associated immune recovery status

  • Ceausu, Andra
  • Rodríguez-Gallego, Esther|||0000-0002-6363-2510
  • Peraire, Joaquim|||0000-0001-7808-5479
  • López-Dupla, M.
  • Domingo Pedrol, Pedro|||0000-0003-1138-5770
  • Viladés, Consuelo|||0000-0002-2991-9593
  • Vidal-Gonzalez, J.
  • Perpiñán, C.
  • Pacheco, Yolanda M.|||0000-0002-9451-8083
  • Veloso, S.
  • Alba, Verónica|||0000-0002-5925-9573
  • Vargas Laguna, Montserrat|||0000-0001-7650-0587
  • Castellano, Alfonso J.
  • Ruiz-Mateos, E.
  • Mallolas Masferrer, Josep|||0000-0002-8365-141X
  • Vidal, Francisco|||0000-0001-8089-4945
  • Rull, A.
A relationship between polymorphisms in genes encoding interleukin 7 (IL-7) and its cellular receptor (IL-7R) and antiretroviral therapy (ART)-associated immune recovery in HIV subjects has been previously reported. However, details of this relationship remain unclear, and the association of these polymorphisms with circulating IL-7/IL-7R levels is scarce. Here, we explored whether IL-7/IL-7R axis was associated with quantitative CD4 T-cell recovery in HIV-infected subjects. IL-7/IL-7R polymorphisms were assessed by genotyping, and multiple inheritance models were used to estimate both, their association with low pre-ART CD4 T-cell counts and incomplete immune recovery status after 48 weeks of suppressive ART. Integrated data from genetic variants association and soluble plasma IL-7/IL-7R quantification suggest that IL-7/IL-7R genotype expression could alter the homeostatic balance between soluble and membrane-bound receptors. The haplotype analyses indicates that allele combinations impacts pre-ART circulating CD4 T-cell counts, immune recovery status and the absolute increment of CD4 T-cell counts. The knowledge about how IL-7/IL-7R axis is related to quantitative CD4 T-cell recovery and immune recovery status after initiating ART could be useful regarding T-cell reservoirs investigations in HIV subjects.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

HIV-1/HAART-Related Lipodystrophy Syndrome (HALS) Is Associated with Decreased Circulating sTWEAK Levels

  • López-Dupla, Miguel
  • Maymó-Masip, Elsa
  • Martínez, Esteban|||0000-0002-6911-8846
  • Domingo Pedrol, Pedro|||0000-0003-1138-5770
  • Leal, Manuel
  • Peraire, Joaquim|||0000-0001-7808-5479
  • Viladés, Consuelo|||0000-0002-2991-9593
  • Veloso Esteban, Sergio|||0000-0001-7943-1169
  • Arnedo, Mireia|||0000-0001-6248-7780
  • Ferrando-Martínez, Sara
  • Beltrán-Debón, Raúl|||0000-0001-9691-1906
  • Alba, Verónica|||0000-0002-5925-9573
  • Gatell, José Mª|||0000-0002-4705-3244
  • Vendrell, Joan|||0000-0002-6994-6115
  • Vidal, Francesc|||0000-0002-6692-6186
  • Chacón, Matilde R.
Obesity and HIV-1/HAART-associated lipodystrophy syndrome (HALS) share clinical, pathological and mechanistic features. Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) is a multifunctional cytokine that plays an important role in obesity and related diseases. We sought to explore the relationship between HALS and circulating levels of soluble (s) TWEAK and its scavenger receptor sCD163. This was a cross-sectional multicenter study of 120 HIV-1-infected patients treated with a stable HAART regimen; 56 with overt HALS and 64 without HALS. Epidemiological and clinical variables were determined. Serum levels of sTWEAK and sCD163 levels were measured by ELISA. Results were analyzed with Student's t -test, Mann-Whitney U and χ 2 test. Pearson and Spearman correlation were used to estimate the strength of association between variables. Circulating sTWEAK was significantly decreased in HALS patients compared with non-HALS patients (2.81±0.2 vs. 2.94±0.28 pg/mL, p = 0.018). No changes were observed in sCD163 levels in the studied cohorts. On multivariate analysis, a lower log sTWEAK concentration was independently associated with the presence of HALS (OR 0.027, 95% CI 0.001-0.521, p = 0.027). HALS is associated with decreased sTWEAK levels.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Increased Circulating Levels of Growth Differentiation Factor 15 in Association with Metabolic Disorders in People Living with HIV Receiving Combined Antiretroviral Therapy

  • Domingo Pedrol, Pedro|||0000-0003-1138-5770
  • Mateo, María Gracia|||0000-0003-1389-9310
  • Villarroya, Joan
  • Cereijo, Rubén|||0000-0002-1108-230X
  • Torres, Ferran|||0000-0002-7355-7913
  • Campderrós, Laura
  • Gallego-Escuredo, José Miguel
  • Gutierrez, Mª del Mar|||0000-0002-0691-1206
  • Mur, Isabel|||0000-0001-7660-8483
  • Corbacho, Noemí
  • Vidal, Francesc|||0000-0002-6692-6186
  • Villarroya, Francesc|||0000-0003-1266-9142
  • Girlat, Marta|||0000-0001-7968-4190
Objective: People living with HIV (PLWH) have an increased cardiovascular risk (CVR) owing to dyslipidemia, insulin resistance, metabolic syndrome, and HIV/combination antiretroviral therapy (cART)-associated lipodystrophy (HALS). Atherosclerosis and inflammation are related to growth differentiation factor-15 (GDF15). The relationship between metabolic disturbances, HALS, and CVR with GDF15 in PLWH is not known. Research design and methods: Circulating GDF15 levels in 152 PLWH (with HALS = 60, without HALS = 43, cART-naïve = 49) and 34 healthy controls were assessed in a cross-sectional study. Correlations with lipids, glucose homeostasis, fat distribution, and CVR were explored. Results: PLWH had increased circulating GDF15 levels relative to controls. The increase was the largest in cART-treated PLWH. Age, homeostatic model assessment of insulin resistance 1 (HOMA1-IR), HALS, dyslipidemia, C-reactive protein, and CVR estimated with the Framingham score correlated with GDF15 levels. The GDF15-Framingham correlation was lost after age adjustment. No correlation was found between GDF15 and the D:A:D Data Collection on Adverse Effects of Anti-HIV Drugs (D:A:D) score estimated CVR. CVR independent predictors were patient group (naïve, HALS-, and HALS+) and cumulated protease inhibitor or nucleoside reverse transcriptase inhibitor exposure. Conclusions: PLWH, especially when cART-treated, has increased GDF15 levels-this increase is associated with dyslipidemia, insulin resistance, metabolic syndrome, HALS, and inflammation-related parameters. GDF15 is unassociated with CVR when age-adjusted.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Pharmacological considerations for the treatment of COVID-19 in people living with HIV (PLWH)

  • Gutierrez, Mª del Mar|||0000-0002-0691-1206
  • Mur, Isabel|||0000-0001-7660-8483
  • Mateo, María Gracia|||0000-0003-1389-9310
  • Vidal, Francesc|||0000-0002-6692-6186
  • Domingo Pedrol, Pedro|||0000-0003-1138-5770
Introduction: When coronavirus infectious disease-2019 (COVID-19) blew up, ill-fated auguries on the collision between COVID-19 and the human immunodeficiency virus (HIV) epidemics loomed. Areas covered: Data from observational studies suggest similar incidence attacks of SARS-CoV-2 infection in people living with HIV (PLWH) and HIV-uninfected populations. The mortality rate of COVID-19 is similar in both populations too. The authors discuss the role of combination antiretroviral therapy (cART) in preventing infection or reducing COVID-19 severity. They also discuss the pharmacological interventions for COVID-19 in PLWH. Expert opinion: Management of COVID-19 in PLWH is no different from the general population. It should be based on careful supportive care, emphasizing lung-protective ventilation, and wise pharmacological interventions. The antiviral drug remdesivir and dexamethasone are the only pharmacological interventions with clinical benefit for COVID-19, whereas anticoagulation may prevent thrombotic complications. The experience with using these drugs in PLWH is limited, which prevents from rendering well-founded conclusions. Until more data on COVID-19 in PLWH become available, the best weapons within our reach are sound supportive care and sensible use of RDV and dexamethasone, bearing in mind the potential for drug-drug interactions of most corticosteroids and antiretroviral drugs.